Anti-inflammatory effect of ondansetron through 5-HT 3 receptors on TNBS-induced colitis in rat

EXCLI Journal

Volumn 11, Issue , 2012, Pages 30-44

  Motavallian Naeini, Azadeh ^a   Minaiyan, Mohsen ^a   Rabbani, Mohammad ^a   Mahzuni, Parvin ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5 HT 3 receptor; Inflammatory bowel diseases; Ondansetron; TNBS induced colitis

Indexed keywords

1 (3 CHLOROPHENYL)BIGUANIDE; DEXAMETHASONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; ONDANSETRON; SEROTONIN 3 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; COLITIS; COLON INJURY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; MICROSCOPY; NONHUMAN; RAT; TREATMENT DURATION;

EID: 84864928187     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AEI, Wallace JL. The chemokine RANTES is a crucial mediator of the pro-gression from acute to chronic colitis in the rat. J Immunol 2001;166:552-8.
2. Ballester I, Daddaoua A, Posadas RL, Nieto A, Suárez MD, Zarzuelo A et al. The bisphosphonate alendronate improves the damage associated with trinitrobenzenesul-fonic acid-induced colitis in rats. Brit J Pharmacol 2007;151;206-15.
3. Baumaqart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and estab-lished and evolving therapies. Lancet 2007;369:1641-57.
4. Bishop AE, Pietroletti R, Taat CW, Brum-melkamp WH, Polak JM. Increased popula-tions of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol 1987;410:391-6.
5. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil con-tent with an enzyme marker. J Invest Derma-tol 1982;78:206-9.
6. Braus NA, Elliott DE. Advances in the path-ogenesis and treatment of IBD. Clin Immunol 2009;132:1-9.
7. Callahan PM, Cunningham KA. Involvement of 5-HT2C receptors in mediating the dis-criminative stimulus properties of m-chlorophenylpiperazine (mCPP). Eur J Phar-macol 1994;257:27-38.
8. Cloez-Tayarani I, Petit-Bertron AF, Venters HD, Cavaillon JM. Differential effect of sero-tonin on cytokine production in lipopolysac-charide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine 2A receptors. Int Immu-nol 2003;15:233-40.
9. Cloez-Tayarani I, Changeux JP. Nicotine and serotonin in immune regulation and inflam-matory processes: a perspective. J Leukoc Biol 2007;81:599-606.
10. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H et al. Molec-ular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syn-drome. Gastroenterology 2004;126:1657-64.
11. Cooper H, Murthy S, Shah R, Sedergran D. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab In-vest 1993;69:238-49.
12. Dieleman L, Palmen M, Akol H, Bloemena E, Pena A, Meuwissen S. Chronic experi-mental colitis induced by dextran sulfate so-dium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-91.
13. Dohi T, Fujihashi K. Type 1 and 2 T helper cell-mediated colitis. Curr Opin Gastroenter-ol 2006;22:651-7.
14. Dubinsky MC. Targeting therapy in pediatric inflammatory bowel disease. Curr Treat Op-tions Gastroenterol 2004;7:391-405.
15. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A et al. On the benefits of silymarin in mu-rine colitis by improving balance of destruc-tive cytokines and reduction of toxic stress in the bowel cells. Centr Eur J Biol 2009;4:204-13.
16. Faerber L, Drechsler S, Ladenburger S, Gschaidmeier H, Fischer W. The neuronal 5-HT3 receptor network after 20 years of re-search-evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007;560:1-8.
17. Fiebich BL, Akundi RS, Lieb K, Candelario-Jalil E, Gmeiner D, Haus U et al. Anti-inflammatory effects of 5-HT3 receptor an-tagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheu-matol Suppl 2004a;119:28-32.
18. Fiebich BL, Akundi RS, Seidel M, Geyer V, Haus U, Müller W et al. Expression of 5-HT3A receptors in cells of the immune sys-tem. Scand J Rheumatol Suppl 2004b;119:9-11.
19. Forbes E, Murase T, Yang M, Matthaei KI, Lee JJ, Lee NA et al. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol 2004; 5664-75.
20. Gebauer A, Merger M, Kilbinger H. Modula-tion of 5-HT3 and 5-HT4 receptors of the re-lease of 5-hydroxytryptamine from the guin-ea-pig small intestine. Naunyn-Schmiede-bergs Arch Pharmacol 1993;347: 137-40.
21. Gershon MD. Roles played by 5-hydroxy-tryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999;13:15-30.
22. Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS. Cofilin pro-motes actin polymerization and defines the direction of cell motility. Science 2004; 304(5671):743-6.
23. Hassani H, Lucas G, Rozell B, Ernfors P. At-tenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. Am J Physiol Gastrointestinal Liver Physiol 2005;288:G550-G556.
24. Hibi T, Ogata H, Sakuraba A. Animal models of inflammatory bowel disease. J Gastroen-terol 2002;37:409-17.
25. Hosseini-Tabatabaei A, Esmaily H, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A et al. Benefit of nicorandil using an immu-nologic murine model of experimental colitis. Centr Eur J Biol 2009;4:74-85.
26. Hrycaj P. Serotonin type 3 receptor antago-nist tropisetron in the treatment of chronic inflammatory rheumatic conditions; prelimi-nary clinical experience. Scand J Rheumatol Suppl 2004;119:55-8.
27. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroen-terol 2000;95:2668-709.
28. Kris MG. Ondansetron: a specific serotonin antagonist for the prevention of chemothera-py-induced vomiting. Important Adv Oncol 1994:165-77.
29. Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S et al. Recent under-standing of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006;12:1068-83.
30. Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is in-creased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastro-intest Liver Physiol 2003;285:G207-G216.
31. Liu FC, Liu FW, Yu HP. Ondansetron atten-uates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model. Resuscitation 2011;82:335-40.
32. Magro F, Fraga S, Azevedo I, Soares-Da-Silva P. Intestinal 5-hydroxytryptamine and mast cell infiltration in rat experimental coli-tis. Dig Dis Sci 2006;51:495-501.
33. Maunder R. Mediators of stress effects in in-flammatory bowel disease: not the usual sus-pects. J Psychosomatic Res 2000;48:569-77.
34. McCleane GJ, Suzuki R, Dickenson AH. Does a single intravenous injection of the 5-HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A dou-ble-blinded, placebo-controlled cross-over study. Anesth Analg 2003;97:1474-8.
35. Minaiyan M, Ghafghazi T. Effects of selec-tive dopamine receptor agonists (D1/DA1) and (D2/DA2) on stress induced gastric le-sions in rats. Physiol Pharmacol 1999;1:1-10.
36. Minaiyan M, Ghannadi AR, Etemad, Mah-zouni P. A study of the effects of Cydonia oblonga Miller (Quince) on TNBS-induced ulcerative colitis in rats. Res Pharm Sci 2012;7 (in press).
37. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
38. Nacife VP, Soeiro MN, Gomes RN, D'Avila H, Castro-Faria Neto HC, Meirelles MN. Morphological and biochemical characteriza-tion of macrophages activated by carrageenan and lipopolysaccharide in vivo. Cell Struct Funct 2004;29:27-34.
39. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:1008-16.
40. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of ac-tive ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007;13:PI13-8.
41. Saeki M, Sakai M, Saito R, Kubota H, Ari-umi H, Takano Y. Effects of HSP-117, a novel tachykinin NK1-receptor antagonist, on cisplatin-induced pica as a new evaluation of delayed emesis in rats. Jpn J Pharmacol 2001;86:359-62.
42. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68-S82.
43. Seidel M, Fiebich BL, Merzenich GU, Can-delario-Jalil E, Koch FW, Vetter H. Seroto-nin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like syno-vial cells. Rheumatol Int 2008;28:1017-22.
44. Vega Lde L, Muñoz E, Calzado MA, Lieb K, Candelario-Jalil E, Gschaidmeir H et al. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol 2005;70:369-80.
45. Wirtz S, Neurath MF. Mouse models of in-flammatory bowel disease. Adv Drug Deliver Rev 2007;59:1073-83.
46. Zheng L, Gao ZQ, Wang SX. A chronic ul-cerative colitis model in rats. World J Gastro-enterol 2000;6:150-2.